Victoria E Scott

Summary

Affiliation: Abbott Laboratories
Country: USA

Publications

  1. ncbi A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats
    Victoria E Scott
    Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Biochem Pharmacol 83:406-18. 2012
  2. ncbi Characterization of human urinary bladder KATP channels containing SUR2B splice variants expressed in L-cells
    Victoria E Scott
    Neuroscience Disease Research AP9A, Rm 218, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064 6125, USA
    Eur J Pharmacol 483:195-205. 2004
  3. ncbi Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder
    Arturo Perez-Medrano
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Med Chem 50:6265-73. 2007
  4. ncbi Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener
    Robert J Altenbach
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 49:6869-87. 2006
  5. ncbi Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597)
    Wende Niforatos
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Mol Pharmacol 71:1209-16. 2007
  6. ncbi [125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: characterization and pharmacology of binding
    Rachel Davis-Taber
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA
    Mol Pharmacol 64:143-53. 2003
  7. ncbi Molecular determinants of species-specific activation or blockade of TRPA1 channels
    Jun Chen
    Neuroscience, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6125, USA
    J Neurosci 28:5063-71. 2008
  8. ncbi Pharmacological characterization of a 1,4-dihydropyridine analogue, 9-(3,4-dichlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydro-1,8(2H,5H)-acridinedione (A-184209) as a novelK(ATP) channel inhibitor
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois, IL 60064, U S A
    Br J Pharmacol 138:393-9. 2003
  9. ncbi Structure-activity studies for a novel series of tricyclic dihydropyridopyrazolones and dihydropyridoisoxazolones as K(ATP) channel openers
    Irene Drizin
    Neuroscience Research, GPRD, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem 12:1895-904. 2004
  10. ncbi (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Illinois 60064, USA
    J Pharmacol Exp Ther 303:379-86. 2002

Collaborators

Detail Information

Publications24

  1. ncbi A-1048400 is a novel, orally active, state-dependent neuronal calcium channel blocker that produces dose-dependent antinociception without altering hemodynamic function in rats
    Victoria E Scott
    Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Biochem Pharmacol 83:406-18. 2012
    ..L-type Ca²⁺ channels can provide robust antinociception in the absence of deleterious effects on hemodynamic or psychomotor function...
  2. ncbi Characterization of human urinary bladder KATP channels containing SUR2B splice variants expressed in L-cells
    Victoria E Scott
    Neuroscience Disease Research AP9A, Rm 218, Abbott Laboratories, 100 Abbott Park Rd, Abbott Park, IL 60064 6125, USA
    Eur J Pharmacol 483:195-205. 2004
    ..This study supports the notion that K(ATP) channels containing SUR2B exon 17- represent a major splice variant expressed in urinary bladder smooth muscle...
  3. ncbi Structure-activity studies of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder
    Arturo Perez-Medrano
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6104, USA
    J Med Chem 50:6265-73. 2007
    ..Preliminary pharmacokinetic studies in dog demonstrated excellent oral bioavailability and a t1/2 of 15 h. The synthesis, SAR studies, and biological properties of these agents are discussed...
  4. ncbi Effects of substitution on 9-(3-bromo-4-fluorophenyl)-5,9-dihydro-3H,4H-2,6-dioxa-4- azacyclopenta[b]naphthalene-1,8-dione, a dihydropyridine ATP-sensitive potassium channel opener
    Robert J Altenbach
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois 60064 6123, USA
    J Med Chem 49:6869-87. 2006
    ..For compound 23b, this profile was mirrored in vivo where it was fully efficacious in inhibiting spontaneous myogenic bladder contractions but only partially able to reduce neurogenically mediated reflex bladder contractions...
  5. ncbi Activation of TRPA1 channels by the fatty acid amide hydrolase inhibitor 3'-carbamoylbiphenyl-3-yl cyclohexylcarbamate (URB597)
    Wende Niforatos
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    Mol Pharmacol 71:1209-16. 2007
    ..In contrast to its effect on TRPA1, URB597 inhibited TRPM8 and had no effects on TRPV1 or TRPV4. Thus, we conclude that URB597 is a novel agonist of TRPA1 and probably activates the channel through a direct gating mechanism...
  6. ncbi [125I]A-312110, a novel high-affinity 1,4-dihydropyridine ATP-sensitive K+ channel opener: characterization and pharmacology of binding
    Rachel Davis-Taber
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois, USA
    Mol Pharmacol 64:143-53. 2003
    ....
  7. ncbi Molecular determinants of species-specific activation or blockade of TRPA1 channels
    Jun Chen
    Neuroscience, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6125, USA
    J Neurosci 28:5063-71. 2008
    ..Therefore, our findings reveal a molecular basis of species-specific channel gating and provide novel insights into how TRPA1 respond to stimuli...
  8. ncbi Pharmacological characterization of a 1,4-dihydropyridine analogue, 9-(3,4-dichlorophenyl)-3,3,6,6-tetramethyl-3,4,6,7,9,10-hexahydro-1,8(2H,5H)-acridinedione (A-184209) as a novelK(ATP) channel inhibitor
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, Illinois, IL 60064, U S A
    Br J Pharmacol 138:393-9. 2003
    ....
  9. ncbi Structure-activity studies for a novel series of tricyclic dihydropyridopyrazolones and dihydropyridoisoxazolones as K(ATP) channel openers
    Irene Drizin
    Neuroscience Research, GPRD, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6101, USA
    Bioorg Med Chem 12:1895-904. 2004
    ..In vitro tests on the tissue from pig bladder strips provided further confirmation of K(ATP) activity of these compounds...
  10. ncbi (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization
    Murali Gopalakrishnan
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Illinois 60064, USA
    J Pharmacol Exp Ther 303:379-86. 2002
    ..The pharmacological profile of A-278637 represents an attractive basis for further investigations of selective K(ATP) channel openers for the treatment of overactive bladder via myogenic etiology...
  11. ncbi Structure-activity relationship of a novel class of naphthyl amide KATP channel openers
    Sean C Turner
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, IL 60064, USA
    Bioorg Med Chem Lett 13:1741-4. 2003
    ..2/SUR2B cells and pig bladder strips. Additionally, A-151892 was found to selectively inhibit unstable bladder contractions in vivo in an obstructed rat model of myogenic bladder function..
  12. ncbi Design and synthesis of novel cyanoguanidine ATP-sensitive potassium channel openers for the treatment of overactive bladder
    Arturo Perez-Medrano
    Abbott Laboratories, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 14:397-400. 2004
    ..These agents are potent full agonists in relaxing electrically-stimulated pig bladder strips. The synthesis, SAR and biological properties of these agents are discussed...
  13. ncbi Characterization of human ASIC2a homomeric channels stably expressed in murine Ltk- cells
    John Malysz
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064, USA
    Life Sci 82:30-40. 2008
    ....
  14. ncbi Differential action potentials and firing patterns in injured and uninjured small dorsal root ganglion neurons after nerve injury
    Xu Feng Zhang
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064, USA
    Brain Res 1009:147-58. 2004
    ....
  15. ncbi Comparative analysis of inactivated-state block of N-type (Ca(v)2.2) calcium channels
    Timothy A Vortherms
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Dept R4PM, Bldg AP9A, 100 Abbott Park Road, Abbott Park, IL 60064 6125, USA
    Inflamm Res 60:683-93. 2011
    ....
  16. ncbi Central pituitary adenylate cyclase 1 receptors modulate nociceptive behaviors in both inflammatory and neuropathic pain states
    Rachel Davis-Taber
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA
    J Pain 9:449-56. 2008
    ..This comprehensive data set demonstrates that if small molecule PAC-1 receptor antagonists could be identified, they would potentially produce broad-spectrum analgesia in both inflammatory and neuropathic pain states...
  17. ncbi Synthesis and SAR of 4-aminocyclopentapyrrolidines as N-type Ca²⁺ channel blockers with analgesic activity
    Xenia Beebe
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 6100, United States
    Bioorg Med Chem 20:4128-39. 2012
    ..Compound 25 is an N-type Ca(2+) channel blocker that produces antinociception in inflammatory and nociceptive pain models without exhibiting cardiovascular or motor liabilities...
  18. ncbi Discovery of diphenyl lactam derivatives as N-type calcium channel blockers
    George A Doherty
    Abbott Laboratories, Global Pharmaceutical Research and Development, Abbott Park, IL 60064, USA
    Bioorg Med Chem Lett 22:1716-8. 2012
    ..Compounds 2, 6 and 7 demonstrated significant efficacy in the capsaicin model of secondary hyperalgesia following oral administration...
  19. ncbi Utility of large-scale transiently transfected cells for cell-based high-throughput screens to identify transient receptor potential channel A1 (TRPA1) antagonists
    Jun Chen
    Neuroscience Research, Abbott Laboratories, Abbott Park, IL 60064 6125, USA
    J Biomol Screen 12:61-9. 2007
    ..The use of LSTT circumvented issues associated with stable TRPA1 expression, increased flexibility and consistency, and greatly reduced labor and cost. This approach will also be applicable to other pharmaceutical targets...
  20. ncbi Discovery and SAR of hydrazide antagonists of the pituitary adenylate cyclase-activating polypeptide (PACAP) receptor type 1 (PAC1-R)
    Xenia Beebe
    Neuroscience Research, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064 1066, USA
    Bioorg Med Chem Lett 18:2162-6. 2008
    ..Previously known antagonists for the PAC(1)-R were slightly truncated peptide ligands. The hydrazides reported here are the first small molecule antagonists ever reported for this class B GPCR...
  21. ncbi An automated electrophysiological assay for differentiating Ca(v)2.2 inhibitors based on state dependence and kinetics
    Andrew M Swensen
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064 6118, USA
    Assay Drug Dev Technol 10:542-50. 2012
    ..This use-dependent protocol also provides information on the kinetics of block development. Data are provided to show how these assays can be utilized to screen for kinetic diversity within and across chemical classes...
  22. ncbi Functional analysis of large conductance Ca2(+)-activated K(+) channels: ion flux studies by atomic absorption spectrometry
    Ashutosh S Parihar
    Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL 60064-6125, USA
    Assay Drug Dev Technol 1:647-54. 2003
    ....
  23. ncbi Solution structure and mutational analysis of pituitary adenylate cyclase-activating polypeptide binding to the extracellular domain of PAC1-RS
    Chaohong Sun
    Global Pharmaceutical Discovery Division, Abbott Laboratories, Abbott Park, IL 60064, USA
    Proc Natl Acad Sci U S A 104:7875-80. 2007
    ....
  24. ncbi A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase
    Karen L Kage
    Neuroscience Research, Global Pharmaceutical Research Division, Abbott Laboratories, Abbott Park, IL 60064, USA
    J Neurosci Methods 161:47-54. 2007
    ..Collectively these data demonstrate that D-AMC can be successfully used to rapidly and effectively identify novel FAAH inhibitors for potential therapeutic use...